Anixa Biosciences, Inc. Logo

Anixa Biosciences, Inc.

ANIX

(0.5)
Stock Price

3,08 USD

-53.96% ROA

-52.41% ROE

-7.99x PER

Market Cap.

99.112.857,00 USD

1.09% DER

0% Yield

-7923.72% NPM

Anixa Biosciences, Inc. Stock Analysis

Anixa Biosciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Anixa Biosciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

Negative ROE (-36.87%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (-37.86%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (3.58x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-624) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Anixa Biosciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Anixa Biosciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Anixa Biosciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Anixa Biosciences, Inc. Revenue
Year Revenue Growth
1985 300.000
1986 100.000 -200%
1987 100.000 0%
1988 100.000 0%
1989 100.000 0%
1990 100.000 0%
1991 100.000 0%
1992 100.000 0%
1993 100.000 0%
1994 100.000 0%
1995 100.000 0%
1996 100.000 0%
1997 100.000 0%
1998 100.000 0%
1999 100.000 0%
2000 1.471.998 93.21%
2001 1.690.768 12.94%
2002 5.186.694 67.4%
2003 244.221 -2023.77%
2004 494.462 50.61%
2005 439.785 -12.43%
2006 508.651 13.54%
2007 486.852 -4.48%
2008 2.063.123 76.4%
2009 1.055.797 -95.41%
2010 730.675 -44.5%
2011 1.003.193 27.17%
2012 940.010 -6.72%
2013 388.850 -141.74%
2014 3.667.320 89.4%
2015 9.255.000 60.37%
2016 300.000 -2985%
2017 362.500 17.24%
2018 1.112.500 67.42%
2019 250.000 -345%
2020 0 0%
2021 512.500 100%
2022 2.469.000.000 99.98%
2023 0 0%
2023 210.000 100%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Anixa Biosciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 2.700.000 100%
1995 2.400.000 -12.5%
1996 3.900.000 38.46%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 1.625.974 100%
2003 1.807.742 10.05%
2004 2.164.427 16.48%
2005 2.266.911 4.52%
2006 4.614.300 50.87%
2007 3.403.943 -35.56%
2008 4.127.393 17.53%
2009 4.116.200 -0.27%
2010 3.007.459 -36.87%
2011 3.124.773 3.75%
2012 2.211.506 -41.3%
2013 0 0%
2014 1.187.320 100%
2015 711.391 -66.9%
2016 1.556.459 54.29%
2017 1.597.550 2.57%
2018 6.813.043 76.55%
2019 5.473.427 -24.47%
2020 4.381.205 -24.93%
2021 6.189.692 29.22%
2022 6.703.000 7.66%
2023 4.352.000 -54.02%
2023 4.769.000 8.74%
2024 7.700.000 38.06%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Anixa Biosciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 2.863.060 100%
2013 7.989.846 64.17%
2014 6.408.861 -24.67%
2015 5.514.555 -16.22%
2016 2.709.841 -103.5%
2017 4.410.682 38.56%
2018 6.911.830 36.19%
2019 5.662.828 -22.06%
2020 5.596.997 -1.18%
2021 7.073.498 20.87%
2022 7.172.000 1.37%
2023 7.024.000 -2.11%
2023 6.291.000 -11.65%
2024 6.668.000 5.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Anixa Biosciences, Inc. EBITDA
Year EBITDA Growth
1985 -1.700.000
1986 -1.800.000 5.56%
1987 -1.200.000 -50%
1988 -1.300.000 7.69%
1989 -1.300.000 0%
1990 -1.600.000 18.75%
1991 -1.600.000 0%
1992 -2.100.000 23.81%
1993 -3.000.000 30%
1994 -3.700.000 18.92%
1995 -3.600.000 -2.78%
1996 -6.500.000 44.62%
1997 -6.600.000 1.52%
1998 -6.900.000 4.35%
1999 -7.600.000 9.21%
2000 -4.823.348 -57.57%
2001 -3.437.733 -40.31%
2002 -401.475 -756.28%
2003 -3.085.996 86.99%
2004 -3.347.991 7.83%
2005 -4.451.058 24.78%
2006 -7.612.544 41.53%
2007 -5.188.678 -46.71%
2008 -6.109.735 15.08%
2009 1.879.798 425.02%
2010 -5.308.073 135.41%
2011 -5.017.773 -5.79%
2012 -4.131.098 -21.46%
2013 -7.917.529 47.82%
2014 -4.721.020 -67.71%
2015 -589.331 -701.08%
2016 -4.137.853 85.76%
2017 -5.687.632 27.25%
2018 -12.779.369 55.49%
2019 -10.586.197 -20.72%
2020 -9.739.961 -8.69%
2021 -13.081.275 25.54%
2022 -13.833.000 5.43%
2023 -11.332.000 -22.07%
2023 -10.965.000 -3.35%
2024 -14.356.000 23.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Anixa Biosciences, Inc. Gross Profit
Year Gross Profit Growth
1985 300.000
1986 100.000 -200%
1987 100.000 0%
1988 100.000 0%
1989 100.000 0%
1990 100.000 0%
1991 100.000 0%
1992 100.000 0%
1993 100.000 0%
1994 200.000 50%
1995 200.000 0%
1996 200.000 0%
1997 400.000 50%
1998 400.000 0%
1999 400.000 0%
2000 1.008.364 60.33%
2001 993.129 -1.53%
2002 3.315.636 70.05%
2003 68.277 -4756.15%
2004 318.350 78.55%
2005 -279.843 213.76%
2006 352.205 179.45%
2007 326.492 -7.88%
2008 1.967.529 83.41%
2009 990.109 -98.72%
2010 648.368 -52.71%
2011 969.112 33.1%
2012 936.137 -3.52%
2013 72.192 -1196.73%
2014 1.679.246 95.7%
2015 5.606.478 70.05%
2016 82.584 -6688.82%
2017 257.944 67.98%
2018 344.090 25.04%
2019 83.750 -310.85%
2020 -90.157 192.89%
2021 127.498 170.71%
2022 2.468.958.000 99.99%
2023 0 0%
2023 49.000 100%
2024 -12.000 508.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Anixa Biosciences, Inc. Net Profit
Year Net Profit Growth
1985 -1.700.000
1986 -1.800.000 5.56%
1987 -1.400.000 -28.57%
1988 -1.300.000 -7.69%
1989 -1.100.000 -18.18%
1990 -1.100.000 0%
1991 -1.300.000 15.38%
1992 -1.800.000 27.78%
1993 -2.800.000 35.71%
1994 -3.400.000 17.65%
1995 -3.000.000 -13.33%
1996 -5.400.000 44.44%
1997 -5.800.000 6.9%
1998 -7.100.000 18.31%
1999 -8.500.000 16.47%
2000 -4.964.173 -71.23%
2001 -3.571.957 -38.98%
2002 -3.285.240 -8.73%
2003 -3.114.411 -5.49%
2004 -3.360.655 7.33%
2005 -4.451.257 24.5%
2006 -7.600.901 41.44%
2007 -5.458.218 -39.26%
2008 -5.821.604 6.24%
2009 -16.489.015 64.69%
2010 -5.175.131 -218.62%
2011 -7.378.036 29.86%
2012 -4.252.799 -73.49%
2013 -10.080.086 57.81%
2014 -9.606.314 -4.93%
2015 -1.379.043 -596.59%
2016 -5.016.428 72.51%
2017 -5.008.991 -0.15%
2018 -13.996.025 64.21%
2019 -11.994.451 -16.69%
2020 -10.132.516 -18.38%
2021 -12.946.631 21.74%
2022 -13.491.000 4.04%
2023 -10.044.000 -34.32%
2023 -9.811.000 -2.37%
2024 -13.108.000 25.15%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Anixa Biosciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 -1
1986 -1 0%
1987 -1 0%
1988 -1 0%
1989 -1 0%
1990 -1 0%
1991 -1 0%
1992 -1 0%
1993 -1 100%
1994 -2 0%
1995 -1 0%
1996 -2 50%
1997 -2 0%
1998 -3 0%
1999 -3 33.33%
2000 -2 -200%
2001 -1 0%
2002 -1 0%
2003 -1 0%
2004 -1 0%
2005 -1 100%
2006 -2 0%
2007 -1 0%
2008 -1 0%
2009 -3 50%
2010 -1 0%
2011 -1 100%
2012 -1 0%
2013 -1 100%
2014 -1 0%
2015 0 0%
2016 -1 0%
2017 0 0%
2018 -1 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Anixa Biosciences, Inc. Free Cashflow
Year Free Cashflow Growth
1989 -1.000.000
1990 -1.100.000 9.09%
1991 -1.200.000 8.33%
1992 -1.800.000 33.33%
1993 -2.700.000 33.33%
1994 -3.700.000 27.03%
1995 -3.000.000 -23.33%
1996 -4.600.000 34.78%
1997 -10.600.000 56.6%
1998 -7.900.000 -34.18%
1999 -6.100.000 -29.51%
2000 -4.871.295 -25.22%
2001 -733.817 -563.83%
2002 -470.038 -56.12%
2003 -959.481 51.01%
2004 -1.220.724 21.4%
2005 -1.724.084 29.2%
2006 -1.858.132 7.21%
2007 -2.410.318 22.91%
2008 -915.721 -163.22%
2009 -2.503.502 63.42%
2010 -2.407.886 -3.97%
2011 -725.028 -232.11%
2012 -3.142.348 76.93%
2013 -3.186.798 1.39%
2014 -2.385.945 -33.57%
2015 1.308.591 282.33%
2016 -3.528.220 137.09%
2017 -3.826.898 7.8%
2018 -4.311.804 11.25%
2019 -4.916.883 12.31%
2020 -6.191.462 20.59%
2021 -4.936.881 -25.41%
2022 -6.492.000 23.95%
2023 -1.445.000 -349.27%
2023 -6.209.000 76.73%
2024 -2.643.000 -134.92%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Anixa Biosciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 -1.000.000
1990 -1.100.000 9.09%
1991 -1.200.000 8.33%
1992 -1.700.000 29.41%
1993 -2.600.000 34.62%
1994 -3.600.000 27.78%
1995 -2.900.000 -24.14%
1996 -4.200.000 30.95%
1997 -10.200.000 58.82%
1998 -7.700.000 -32.47%
1999 -6.100.000 -26.23%
2000 -4.840.578 -26.02%
2001 -717.845 -574.32%
2002 -431.471 -66.37%
2003 -958.501 54.98%
2004 -1.205.122 20.46%
2005 -1.720.332 29.95%
2006 -1.847.108 6.86%
2007 -2.396.859 22.94%
2008 -901.868 -165.77%
2009 -2.501.566 63.95%
2010 -2.405.817 -3.98%
2011 -716.000 -236.01%
2012 -3.140.748 77.2%
2013 -3.186.798 1.45%
2014 -2.379.261 -33.94%
2015 1.363.367 274.51%
2016 -3.381.699 140.32%
2017 -3.796.710 10.93%
2018 -4.273.400 11.15%
2019 -4.741.426 9.87%
2020 -6.175.671 23.22%
2021 -4.936.881 -25.09%
2022 -6.492.000 23.95%
2023 -1.445.000 -349.27%
2023 -6.209.000 76.73%
2024 -2.643.000 -134.92%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Anixa Biosciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 0
1990 0 0%
1991 0 0%
1992 100.000 100%
1993 100.000 0%
1994 100.000 0%
1995 100.000 0%
1996 400.000 75%
1997 400.000 0%
1998 200.000 -100%
1999 0 0%
2000 30.717 100%
2001 15.972 -92.32%
2002 38.567 58.59%
2003 980 -3835.41%
2004 15.602 93.72%
2005 3.752 -315.83%
2006 11.024 65.97%
2007 13.459 18.09%
2008 13.853 2.84%
2009 1.936 -615.55%
2010 2.069 6.43%
2011 9.028 77.08%
2012 1.600 -464.25%
2013 0 0%
2014 6.684 100%
2015 54.776 87.8%
2016 146.521 62.62%
2017 30.188 -385.36%
2018 38.404 21.39%
2019 175.457 78.11%
2020 15.791 -1011.12%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Anixa Biosciences, Inc. Equity
Year Equity Growth
1985 3.100.000
1986 1.300.000 -138.46%
1987 1.100.000 -18.18%
1988 2.000.000 45%
1989 4.100.000 51.22%
1990 4.100.000 0%
1991 4.200.000 2.38%
1992 4.100.000 -2.44%
1993 8.200.000 50%
1994 6.400.000 -28.13%
1995 9.400.000 31.91%
1996 22.800.000 58.77%
1997 18.800.000 -21.28%
1998 11.900.000 -57.98%
1999 6.300.000 -88.89%
2000 5.557.599 -13.36%
2001 4.166.526 -33.39%
2002 2.317.490 -79.79%
2003 1.988.206 -16.56%
2004 1.872.930 -6.15%
2005 1.118.023 -67.52%
2006 1.281.841 12.78%
2007 1.191.350 -7.6%
2008 1.730.277 31.15%
2009 4.452.272 61.14%
2010 4.595.955 3.13%
2011 1.058.033 -334.39%
2012 -1.194.056 188.61%
2013 -3.320.593 64.04%
2014 4.009.573 182.82%
2015 5.053.601 20.66%
2016 987.475 -411.77%
2017 7.922.923 87.54%
2018 5.183.431 -52.85%
2019 4.812.378 -7.71%
2020 8.264.373 41.77%
2021 34.766.794 76.23%
2022 28.200.000 -23.29%
2023 23.371.000 -20.66%
2023 24.585.000 4.94%
2024 20.691.000 -18.82%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Anixa Biosciences, Inc. Assets
Year Assets Growth
1985 3.300.000
1986 1.500.000 -120%
1987 1.200.000 -25%
1988 2.100.000 42.86%
1989 4.200.000 50%
1990 4.200.000 0%
1991 4.300.000 2.33%
1992 4.400.000 2.27%
1993 8.700.000 49.43%
1994 6.600.000 -31.82%
1995 9.700.000 31.96%
1996 24.700.000 60.73%
1997 20.000.000 -23.5%
1998 13.300.000 -50.38%
1999 8.100.000 -64.2%
2000 6.894.501 -17.48%
2001 6.562.403 -5.06%
2002 2.731.509 -140.25%
2003 2.330.491 -17.21%
2004 2.316.050 -0.62%
2005 1.466.253 -57.96%
2006 1.863.629 21.32%
2007 1.870.159 0.35%
2008 7.497.869 75.06%
2009 9.848.446 23.87%
2010 10.046.076 1.97%
2011 8.645.832 -16.2%
2012 5.660.676 -52.73%
2013 5.439.538 -4.07%
2014 9.055.356 39.93%
2015 9.335.570 3%
2016 5.628.107 -65.87%
2017 8.812.416 36.13%
2018 6.448.542 -36.66%
2019 6.293.693 -2.46%
2020 9.452.964 33.42%
2021 36.257.404 73.93%
2022 30.412.000 -19.22%
2023 25.522.000 -19.16%
2023 26.578.000 3.97%
2024 22.908.000 -16.02%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Anixa Biosciences, Inc. Liabilities
Year Liabilities Growth
1985 200.000
1986 200.000 0%
1987 100.000 -100%
1988 100.000 0%
1989 100.000 0%
1990 100.000 0%
1991 100.000 0%
1992 300.000 66.67%
1993 500.000 40%
1994 200.000 -150%
1995 300.000 33.33%
1996 1.900.000 84.21%
1997 1.200.000 -58.33%
1998 1.400.000 14.29%
1999 1.800.000 22.22%
2000 1.336.902 -34.64%
2001 2.395.877 44.2%
2002 414.019 -478.69%
2003 342.285 -20.96%
2004 443.120 22.76%
2005 348.230 -27.25%
2006 581.788 40.14%
2007 678.809 14.29%
2008 5.767.592 88.23%
2009 5.396.174 -6.88%
2010 5.450.121 0.99%
2011 7.587.799 28.17%
2012 6.854.732 -10.69%
2013 8.760.131 21.75%
2014 5.045.783 -73.61%
2015 4.281.969 -17.84%
2016 4.640.632 7.73%
2017 889.493 -421.72%
2018 1.265.111 29.69%
2019 1.481.315 14.6%
2020 1.188.591 -24.63%
2021 1.490.610 20.26%
2022 2.212.000 32.61%
2023 2.151.000 -2.84%
2023 1.993.000 -7.93%
2024 2.217.000 10.1%

Anixa Biosciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.39
Price to Earning Ratio
-7.99x
Price To Sales Ratio
635.34x
POCF Ratio
-11.79
PFCF Ratio
-11.83
Price to Book Ratio
4.53
EV to Sales
629.01
EV Over EBITDA
-7.17
EV to Operating CashFlow
-11.71
EV to FreeCashFlow
-11.71
Earnings Yield
-0.13
FreeCashFlow Yield
-0.08
Market Cap
0,10 Bil.
Enterprise Value
0,10 Bil.
Graham Number
2.43
Graham NetNet
0.59

Income Statement Metrics

Net Income per Share
-0.39
Income Quality
0.68
ROE
-0.52
Return On Assets
-0.54
Return On Capital Employed
-0.66
Net Income per EBT
0.99
EBT Per Ebit
0.91
Ebit per Revenue
-87.94
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
46.05
Research & Developement to Revenue
41.89
Stock Based Compensation to Revenue
29.47
Gross Profit Margin
0.74
Operating Profit Margin
-87.94
Pretax Profit Margin
-80.17
Net Profit Margin
-79.24

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.26
Free CashFlow per Share
-0.26
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.62
Return on Tangible Assets
-0.54
Days Sales Outstanding
959.29
Days Payables Outstanding
2755.75
Days of Inventory on Hand
0
Receivables Turnover
0.38
Payables Turnover
0.13
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,65
Book Value per Share
0,65
Tangible Book Value per Share
0.65
Shareholders Equity per Share
0.68
Interest Debt per Share
0.01
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.07
Current Ratio
11.31
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
20904000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Anixa Biosciences, Inc. Dividends
Year Dividends Growth

Anixa Biosciences, Inc. Profile

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

CEO
Dr. Amit Kumar Ph.D.
Employee
4
Address
3150 Almaden Expressway
San Jose, 95118

Anixa Biosciences, Inc. Executives & BODs

Anixa Biosciences, Inc. Executives & BODs
# Name Age
1 Dr. Pamela D. Garzone Ph.D.
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board
70
2 Mr. Michael J. Catelani CPA, MBA
President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary
70
3 Dr. Amit Kumar Ph.D.
Chief Executive Officer, Chairman & Co-Chair of CBAB
70
4 Mr. John Roop
Senior Vice President of Engineering
70

Anixa Biosciences, Inc. Competitors